Epirubicin is linked in the source record to Breast Cancer, with the principal indications stated as Breast cancer and selected other solid tumors. Its action is described as follows: Intercalates DNA, inhibits topoisomerase II and generates free radicals. The pharmacologic action described for this medicine provides the basis for its use in the malignancies and treatment settings listed in the database. Pharmacologically, it is a anthracycline and is categorized as Chemotherapy; Anthracycline; Topoisomerase Inhibitor. The regimen field identifies FEC/FEC-T; EC/EC-T; breast cancer anthracycline regimens. The clinical importance of those combinations is that treatment partners can determine how the medicine is positioned within a larger oncology program. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. The indication should be read as a complete clinical statement, particularly where it contains receptor, mutation, stage, prior-treatment, or disease-status requirements. A class label alone cannot establish that a drug is appropriate for a particular patient or tumor. This entry provides an original reference summary based on the supplied clinical fields and does not substitute for current prescribing information. No individualized dose, dose adjustment, or administration instruction is included.